Foresee Pharmaceuticals Receives the Second Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion for the Treatment of Central Precocious Puberty ...Middle East

The independent Data and Safety Monitoring Board (DSMB) recommended the continuation of patient enrollment as planned. There has been no safety concern with the use of Leuprolide (FP-001) injectable Emulsion in pediatric CPP patients. TAIPEI, Nov. 15, 2024 /PRNewswire/ -- Foresee...

Hence then, the article about foresee pharmaceuticals receives the second positive recommendation from dsmb to continue the casppian study a phase 3 clinical trial of leuprolide fp 001 injectable emulsion for the treatment of central precocious puberty was published today ( Friday 15/11/2024 - 12:13 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Foresee Pharmaceuticals Receives the Second Positive Recommendation from DSMB to Continue the Casppian Study, a Phase 3 Clinical Trial of Leuprolide (FP-001) Injectable Emulsion for the Treatment of Central Precocious Puberty )

Also on site :

• Box Office Smash That ‘Saved Cinema’ Is Now Streaming Free for the First Time Ever
• Elon Musk’s SpaceX unveils filing for blockbuster IPO
• Samsung dodges global AI chip shock